Related Experiment Video
Updated: Oct 3, 2025
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.5K
Real-World Practice of Hypofractionated Radiotherapy in Patients With Invasive Breast Cancer.
Fang Chen1,2, Timothy S K Hui1, Lingyu Ma1
1Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Frontiers in Oncology
|February 21, 2022
Summary
Hypofractionated radiotherapy (HFRT) shows comparable outcomes to conventionally fractionated radiotherapy (CFRT) for breast cancer (BC) patients. This real-world study found no significant differences in recurrence-free survival or disease-free survival between HFRT and CFRT.
Area of Science:
- Oncology
- Radiotherapy
- Breast Cancer Research
Background:
- Hypofractionated radiotherapy (HFRT) is increasingly used for breast cancer (BC).
- Real-world data on HFRT practices in early and locally advanced BC are limited.
- Understanding HFRT's effectiveness compared to conventional methods is crucial.
Purpose of the Study:
- To evaluate the real-world application of HFRT in early and locally advanced breast cancer.
- To compare the oncologic outcomes of HFRT versus conventionally fractionated radiotherapy (CFRT).
- To assess locoregional recurrence-free survival (LRRFS) and disease-free survival (DFS) in a diverse BC patient cohort.
Main Methods:
- Retrospective review of 1,010 invasive BC patients treated between 2015 and 2019.
- Comparison of outcomes between patients receiving HFRT and CFRT.
- Kaplan-Meier analysis for LRRFS and DFS, with Log-rank tests and univariate/multivariable analyses for treatment effect.
Main Results:
- 89.4% of patients received HFRT.
- No significant difference in 4-year LRRFS between HFRT (1.5%) and CFRT (3.8%) groups (p=0.23).
- No significant difference in 4-year DFS between HFRT (93.5%) and CFRT (89.9%) groups (p=0.17), except for a trend towards lower DFS in triple-negative N2-3 BC patients treated with HFRT.
Conclusions:
- HFRT demonstrates comparable LRRFS and DFS to CFRT in breast cancer patients post-surgery.
- These findings hold true across different nodal stages and molecular subtypes in locally advanced BC.
- HFRT is a viable alternative to CFRT for a broad range of breast cancer patients.
